A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Clinical trial NCT03122522 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03122522
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-17
- Primary completion
- 2027-04-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.